Double specific antibody "sucks gold" again! A round of financing of 25 million US dollars for Anmai biology

Source: on April 25, 2017-04-26 of MedStar, an Mai biology announced the completion of round a financing of US $25 million This round of financing is led by Yuanhe origin, followed by Decheng capital, Bencao capital and trend investment Through this round of financing, Anmai biology will further promote its own development of bispecific antibody research and development platform, and build the development pipeline of therapeutic antibody drugs for tumor immunity and other related fields It is expected that the leading project independently developed by the company will carry out phase I clinical trial in 2018 After this round of financing, Dr Li Ning of Yuanhe origin and Dr Cui Xiangmin of Decheng capital will join the board of directors of Anmai biology and become the new members of the board of directors, including Dr Wu Chenbing, the founding president of the company, Dr Robert Kamen, the former president of Abbott biology research and development center, and Dr Xu Yajun, the co-founder It is understood that the fit Ig (Fabs in tandem immunoglobulin) technology independently developed by Anmai biology is a unique and efficient innovative platform technology for the development of bispecific antibody products This technology can develop double antibody molecules with higher activity, lower immunogenicity and easier mass production Not long ago, Wu Chenbing, CEO of Anmai biology, revealed the reason why he founded Anmai biology and chose to develop bispecific antibody in an interview with biological exploration "The selection of bispecific antibodies is mainly based on three considerations: first, their own experience, second, their technical advantages, and third, the irreplaceable biological mechanism of the drugs themselves," he said Fit Ig technology borrows some structural characteristics of the antibody itself, makes full use of the integrity and stability of the structure of fab, and reassembles it at the gene level through cross combination in space Finally, the Fab cross-linked molecular structure is generated Wu Chenbing said that such a design ensures the correct matching of heavy chain and light chain in the double antibody technology, as well as the subsequent problems of drug-making and mass production At present, the main area of product development of Anmai biology is tumor The company hopes to develop the second generation of targeted therapy products through its own technology platform Compared with the first generation of targeted therapy monoclonal antibody that has been listed now, the company will at least show great advantages in the pre clinical animal model; at the same time, it hopes that this advantage will eventually translate into a substantial improvement in clinical efficacy As an important part of Biopharmaceutics, antibody drugs have become the gold industry Wu Chenbing believes that in the next 10-20 years at least, the antibody market will have a great leap forward Looking back on the development history of antibody drugs in China for more than ten years, it is mainly focused on the development of bio generic drugs The development of innovative antibody drugs, including new molecules such as bispecific antibodies, is just in its infancy, and there is still much room for development in the future.